Want to see SE:SANION full AI Analyst Report?
SANION Stock Chart & Stats
kr11.61
kr0.56(4.17%)
At close: 4:00 PM EDT
kr11.61
kr0.56(4.17%)
Day’s Range― - ―
52-Week Rangekr9.46 - kr28.30
Previous CloseN/A
Volume166.26K
Average Volume (3M)461.52K
Market Cap
kr1.39B
Enterprise Valuekr1.32K
Total Cash (Recent Filing)kr486.31M
Total Debt (Recent Filing)kr0.00
Price to Earnings (P/E)7.4
Beta0.41
Next Earnings
Nov 26, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)1.34
Shares Outstanding138,030,140
10 Day Avg. Volume475,201
30 Day Avg. Volume461,522
Financial Highlights & Ratios
PEG Ratio0.39
Price to Book (P/B)4.30
Price to Sales (P/S)6.29
P/FCF Ratio13.64
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)kr267.00M
Bulls Say, Bears Say
Bulls Say
Strong Current ProfitabilityThe sharp improvement to high net and EBIT margins provides meaningful current earnings power and could support continued investment in the pipeline. If profitability reflects repeatable partnering economics and disciplined spending, it strengthens Saniona’s ability to operate without relying solely on new capital.
Debt-free Balance SheetA debt-free structure and substantial equity cushion reduce financial pressure while Saniona advances clinical programs and seeks partners. Lower leverage limits interest and refinancing burdens, preserving flexibility to fund research, negotiate partnerships, and withstand uneven biotechnology cash flows.
Positive Cash GenerationPositive operating and free cash flow across the latest reported periods indicates that Saniona has recently generated internal funding rather than depending entirely on external financing. Sustained cash generation would improve resilience and provide greater choice in advancing programs or pursuing collaborations.
Bears Say
Extreme Revenue VolatilityA sharp TTM revenue decline makes current earnings difficult to extrapolate and reduces visibility into the company’s underlying operating trajectory. Because licensing and milestone income can be uneven, Saniona may experience substantial swings in revenue and profitability between partnership events.
Inconsistent Cash ConversionCash flow below net income means reported profits are not converting fully into available cash, while the year-to-year swings show limited consistency. This can constrain reliable self-funding of research and increase the importance of financing or partnership proceeds when cash needs rise.
Recent Capital-structure InstabilityThe history of leverage and negative equity shows that Saniona’s financial position has been vulnerable to sharp deterioration, even though it is currently conservative. Such instability raises concern that weak operating or partnership results could again pressure equity and limit strategic flexibility.
Saniona AB News
SANION FAQ
What was Saniona AB’s price range in the past 12 months?
Saniona AB lowest stock price was kr9.46 and its highest was kr28.30 in the past 12 months.
What is Saniona AB’s market cap?
Saniona AB’s market cap is kr1.39B.
When is Saniona AB’s upcoming earnings report date?
Saniona AB’s upcoming earnings report date is Nov 26, 2026 which is in 62 days.
How were Saniona AB’s earnings last quarter?
Saniona AB released its earnings results on Aug 27, 2026. The company reported -kr0.422 earnings per share for the quarter.
Is Saniona AB overvalued?
According to Wall Street analysts Saniona AB’s price is currently Overvalued.
Does Saniona AB pay dividends?
Saniona AB does not currently pay dividends.
What is Saniona AB’s EPS estimate?
Saniona AB’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Saniona AB have?
Saniona AB has 138,030,140 shares outstanding.
What happened to Saniona AB’s price movement after its last earnings report?
Saniona AB reported an EPS of -kr0.422 in its last earnings report. Following the earnings report the stock price went up 0.761%.
Which hedge fund is a major shareholder of Saniona AB?
Currently, no hedge funds are holding shares in SE:SANION
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
Saniona AB
Saniona AB (publ), founded in 2011 and based in Glostrup, Denmark, is a biopharmaceutical company focused on rare diseases. It specializes in discovering, developing, and commercializing treatments specifically targeting central nervous system disorders. The company's pipeline features Tesofensine, a monoamine reuptake inhibitor, and Tesomet, a fixed-dose combination of tesofensine and metoprolol, which has advanced through Phase 2 clinical trials for Prader-Willi Syndrome and hypothalamic obesity. Additionally, Saniona is progressing SAN711, currently in Phase 1 for rare neuropathic conditions, and SAN903, an early-stage candidate in preclinical development for rare inflammatory, fibrotic, and hematological ailments. Saniona also engages in various strategic collaborations, including research and partnership agreements with Boehringer Ingelheim International GmbH, a licensing deal with Productos Medix, S.A. de C.V., and both research services and collaboration agreements with Cephagenix ApS.
Technical Analysis
Hansa Biopharma AB
―
Medivir AB
―
Camurus AB
―
AlzeCure Pharma AB
―
BioArctic AB Class B
―